000153294 001__ 153294
000153294 005__ 20230915094011.0
000153294 0247_ $$2pmc$$apmc:PMC7351505
000153294 0247_ $$2doi$$a10.3389/fpsyt.2020.00576
000153294 0247_ $$2altmetric$$aaltmetric:85682752
000153294 0247_ $$2pmid$$apmid:32714214
000153294 037__ $$aDZNE-2020-01291
000153294 041__ $$aEnglish
000153294 082__ $$a610
000153294 1001_ $$0P:(DE-HGF)0$$aHansen, Niels$$b0$$eCorresponding author
000153294 245__ $$aFigural Memory Impairment in Conjunction With Neuropsychiatric Symptoms in IgLON5 Antibody-Associated Autoimmune Encephalitis
000153294 260__ $$aLausanne$$bFrontiers Research Foundation$$c2020
000153294 3367_ $$2DRIVER$$aarticle
000153294 3367_ $$2DataCite$$aOutput Types/Journal article
000153294 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1605878121_21604
000153294 3367_ $$2BibTeX$$aARTICLE
000153294 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000153294 3367_ $$00$$2EndNote$$aJournal Article
000153294 520__ $$aBackground: IgLON5 disease is an autoimmune disorder that shares neuropathological aspects with a tauopathy. Its clinical spectrum is heterogeneous, and figural memory impairment as an initial phenomenon of IgLON5 syndrome has not yet been described. The rationale of this report is to highlight symptoms related to IgLON5 disease that have not been reported to date. This case report will thereby emphasize how important it is to initiate thorough diagnostic methods including cerebrospinal fluid analysis (CSF) before starting early immunotherapy.Methods: We examined a 65-year-old Caucasian male via neuropsychological tests, magnetic resonance imaging (MRI), electroencephalography (EEG), neurography and polysomnography. He also underwent two lumbar punctures from which we determined specific autoantibodies in cerebrospinal (CSF) and peripheral blood (PB).Results: The patient presented initially complaining of memory loss, gradual dysphagia and sleeping dysfunction. Neuropsychological testing at first presentation and follow-up revealed subtle figural and working memory impairment. At onset and at his 6-month follow-up, we detected IgLON5 antibodies in CSF and PB. Furthermore, we identified in the CSF a blood–brain barrier disturbance at disease onset and follow-up, and markers of neuroaxonal damage such as mildly elevated phosphorylated Tau-181 protein with 86 pg/ml (normal range ≤ 61 pg/ml) at onset. Three months after his initial presentation, he was suffering from axonal neuropathy and transient ataxia in the extremities. Assuming a definitive autoimmune encephalitis-associated with anti-IgLON5 antibodies, we applied high-dose steroids monthly (1g methylprednisolone i.v. for five consecutive days) and his memory complaints, ataxia of extremities and peripheral neuropathy as well as sleeping dysfunction decreased.Conclusions: Our findings broaden IgLON5 disease’s clinical spectrum to include predominant and discrete figural memory impairment together with sleeping dysfunction at disease onset. In addition, our report illustrates how important taking an elaborated diagnostic approach is to assuring an accurate diagnosis and the appropriate therapy if a patient presents with a persisting figural memory impairment and sleeping abnormalities so as to avoid overlooking IgLON5 disease and a potentially poor outcome.
000153294 536__ $$0G:(DE-HGF)POF3-342$$a342 - Disease Mechanisms and Model Systems (POF3-342)$$cPOF3-342$$fPOF III$$x0
000153294 536__ $$0G:(DE-HGF)POF3-344$$a344 - Clinical and Health Care Research (POF3-344)$$cPOF3-344$$fPOF III$$x1
000153294 588__ $$aDataset connected to CrossRef
000153294 7001_ $$aHirschel, Sina$$b1
000153294 7001_ $$aStöcker, Winfried$$b2
000153294 7001_ $$aManig, Anja$$b3
000153294 7001_ $$aFalk, Hannah Sönne$$b4
000153294 7001_ $$aErnst, Marielle$$b5
000153294 7001_ $$aVukovich, Ruth$$b6
000153294 7001_ $$0P:(DE-HGF)0$$aZerr, Inga$$b7
000153294 7001_ $$0P:(DE-2719)2811317$$aWiltfang, Jens$$b8$$udzne
000153294 7001_ $$0P:(DE-HGF)0$$aBartels, Claudia$$b9
000153294 773__ $$0PERI:(DE-600)2564218-2$$a10.3389/fpsyt.2020.00576$$gVol. 11, p. 576$$p576$$tFrontiers in psychiatry$$v11$$x1664-0640$$y2020
000153294 8564_ $$uhttps://www.frontiersin.org/articles/10.3389/fpsyt.2020.00576/full
000153294 8564_ $$uhttps://pub.dzne.de/record/153294/files/7081.pdf$$yOpenAccess
000153294 8564_ $$uhttps://pub.dzne.de/record/153294/files/7081.gif?subformat=icon$$xicon$$yOpenAccess
000153294 8564_ $$uhttps://pub.dzne.de/record/153294/files/7081.jpg?subformat=icon-1440$$xicon-1440$$yOpenAccess
000153294 8564_ $$uhttps://pub.dzne.de/record/153294/files/7081.jpg?subformat=icon-180$$xicon-180$$yOpenAccess
000153294 8564_ $$uhttps://pub.dzne.de/record/153294/files/7081.jpg?subformat=icon-640$$xicon-640$$yOpenAccess
000153294 8564_ $$uhttps://pub.dzne.de/record/153294/files/7081.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000153294 909CO $$ooai:pub.dzne.de:153294$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000153294 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811317$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000153294 9131_ $$0G:(DE-HGF)POF3-342$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$aDE-HGF$$bForschungsbereich Gesundheit$$lErkrankungen des Nervensystems$$vDisease Mechanisms and Model Systems$$x0
000153294 9131_ $$0G:(DE-HGF)POF3-344$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$aDE-HGF$$bForschungsbereich Gesundheit$$lErkrankungen des Nervensystems$$vClinical and Health Care Research$$x1
000153294 9141_ $$y2020
000153294 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2020-09-06
000153294 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000153294 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-09-06
000153294 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-09-06
000153294 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-09-06
000153294 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2020-09-06
000153294 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT PSYCHIATRY : 2021$$d2022-11-26
000153294 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-26
000153294 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-26
000153294 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-05-12T10:47:58Z
000153294 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-05-12T10:47:58Z
000153294 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2021-05-12T10:47:58Z
000153294 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-26
000153294 915__ $$0StatID:(DE-HGF)1180$$2StatID$$aDBCoverage$$bCurrent Contents - Social and Behavioral Sciences$$d2022-11-26
000153294 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-26
000153294 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-26
000153294 915__ $$0StatID:(DE-HGF)0130$$2StatID$$aDBCoverage$$bSocial Sciences Citation Index$$d2022-11-26
000153294 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bFRONT PSYCHIATRY : 2021$$d2022-11-26
000153294 9201_ $$0I:(DE-2719)6000014$$kGöttingen Pre 2020$$lGöttingen Pre 2020$$x0
000153294 9201_ $$0I:(DE-2719)1440011-1$$kAG Zerr$$lTranslational Studies and Biomarkers$$x1
000153294 9201_ $$0I:(DE-2719)1410006$$kAG Wiltfang$$lAlzheimer Biomarker and Clinical Study Group$$x2
000153294 980__ $$ajournal
000153294 980__ $$aVDB
000153294 980__ $$aUNRESTRICTED
000153294 980__ $$aI:(DE-2719)6000014
000153294 980__ $$aI:(DE-2719)1440011-1
000153294 980__ $$aI:(DE-2719)1410006
000153294 9801_ $$aFullTexts